When a cell is damaged beyond repair — by radiation, oxidative stress, telomere shortening, or oncogene activation — it has two healthy options. It can die (apoptosis) or it can stop dividing and sit quietly (quiescence). But some damaged cells choose a third path. They enter senescence.
A senescent cell is alive but dysfunctional. It can't divide. It can't contribute to tissue maintenance. And worst of all, it secretes a cocktail of inflammatory molecules called the SASP — senescence-associated secretory phenotype. This cocktail includes cytokines, chemokines, growth factors, and proteases that damage nearby healthy cells and push them toward senescence too.
It's contagious dysfunction. One zombie cell creates more zombie cells. The burden grows exponentially with age.
By your 60s, senescent cells are a significant contributor to chronic inflammation, tissue fibrosis, reduced stem cell function, and increased cancer risk. They're a small percentage of your total cells — maybe 1-2% — but they punch far above their weight.
In 2016, researchers at the Mayo Clinic published a study that sent shockwaves through aging research. They used a genetic technique to selectively clear senescent cells from naturally aging mice. The results were staggering.
Mice with cleared senescent cells lived 25-30% longer. Their organs functioned like younger animals. Kidney function improved. Heart function improved. They developed fewer cataracts and tumours. They were physically more active. Their fur looked better.
This wasn't a drug. It was a genetic kill switch. But it proved the concept: if you remove senescent cells, the body gets measurably younger. Not just slower at aging. Younger.
The race to find drugs that could replicate this effect was on.
The first clinically tested senolytic combination was dasatinib (a leukaemia drug) plus quercetin (a plant flavonoid). Together, they target the survival pathways that senescent cells use to resist apoptosis. Healthy cells aren't dependent on these pathways, so they're largely spared.
In a 2019 pilot study at the Mayo Clinic, dasatinib + quercetin (D+Q) cleared senescent cells in patients with diabetic kidney disease. Patients showed reduced SASP markers and improved tissue function after just three days of treatment. Three days.
Fisetin — a flavonoid found in strawberries — is the other leading candidate. Preclinical data showed it cleared senescent cells as effectively as D+Q with potentially fewer side effects. The AFFIRM trial, a large-scale fisetin study for age-related frailty, has been running since 2023 with results expected soon.
The dosing protocol matters. Senolytics aren't taken daily like supplements. They're taken in short bursts — two or three days every few weeks or months. The goal is to periodically sweep out the zombie cells, then let your body rebuild with healthy ones. Hit and run.
Senescent cells aren't entirely useless. They play roles in wound healing, embryonic development, and potentially tumour suppression. Clearing them too aggressively, or at the wrong time, could have unintended consequences.
Dasatinib is a chemotherapy drug with known side effects — nausea, fatigue, fluid retention. The doses used in senolytic protocols are lower than cancer treatment, but it's not a supplement you can buy at a health food store. It requires medical supervision.
Fisetin is gentler and available over the counter, but the human data is still limited. Most people self-experimenting with fisetin are basing their doses on mouse data scaled to human body weight. That's not the same as a clinical dose-finding study.
Senolytics are real. The mechanism is proven. The early human data is encouraging. But we're still early. The smart move is to watch the trials, not become one. Unless you're working with a physician who understands the science — in which case, the conversation is worth having.
Evidence-based health research, supplement guides & new articles — straight to your inbox.